GlaxoSmithKline and Sanofi said Wednesday that they plan to submit their long-awaited Covid-19 vaccine for U.S. and European regulatory approval, and announced data that suggest that their vaccine could be a strong contender in the Covid-19 booster market.
That could disrupt the plans of Moderna (ticker: MRNA) and the other messenger RNA-based Covid-19 vaccine makers, which see a future for messenger RNA-based Covid-19 boosters lasting long after the pandemic ends.
Sanofi…